• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immunovant, Inc. - Common Stock (NQ:IMVT)

    18.94 +0.20 (+1.07%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Immunovant, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Why Immunovant Stock Blasted Higher Today
    The biotech looks as if it has a promising treatment for an autoimmune disorder. 
    Via The Motley Fool
    Immunovant Posts 34% R&D Jump in Q1
    Via The Motley Fool
    Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence
    The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share. 
    Via Stocktwits
    Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
     
    Via Benzinga
    Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
    The company is getting a new chief executive and a new chief financial officer amid sweeping changes. 
    Via Investor's Business Daily
    Topics Government
    Four Stocks To Watch This Week - Monday, Sep. 23
    For this week, we expect a slight pause in momentum, though nothing particularly dramatic. 
    Via Talk Markets
    Top 2 Health Care Stocks That May Collapse This Quarter
     
    Via Benzinga
    Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated
    Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company. 
    Via Stocktwits
    Topics Government Retirement Stocks
    Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
    Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402. 
    Via Benzinga
    Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
    The companies reported positive results for their lead asset in patients with two rare diseases. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Recap: Immunovant Q3 Earnings
     
    Via Benzinga
    Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
    Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced. 
    Via Investor's Business Daily
    High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What
    With inflation and jobs behind us, it’s time to shift our focus 6,700 miles west to Tokyo. The Bank of Japan appears poised for another rate hike next week, with odds now at 77%. Monitor the VIX for... 
    Via Talk Markets
    Topics Economy Stocks
    Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
    Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
    Via Investor's Business Daily
    What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
    Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the... 
    Via Benzinga
    After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
    Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
    Via Investor's Business Daily
    IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024
    IMVT stock results show that Immunovant missed analyst estimates for earnings per share the fourth quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
     
    Via Benzinga
    Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
    Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
    Via Benzinga
    Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
     
    Via Benzinga
    Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday
     
    Via Benzinga
    Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
    The company says it's still running additional testing of the drug, calling the results "positive." 
    Via Investor's Business Daily
    Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
    Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
    Via InvestorPlace
    Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
    Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
    Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
    Via InvestorPlace
    7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
    Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. 
    Via InvestorPlace
    3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
    Analyst ratings tell investors which stocks institutional investors like, here are three top-rated Russell 2000 stocks to consider in 2024 
    Via InvestorPlace
    5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
    These five biotech companies could have a lot of room to run. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.